Cipla Limited

CIPLA

INE059A01026

Pharmaceuticals

Delayed NSE India S.E. Other stock markets 03:11:48 2024-05-29 am EDT			5-day change	1st Jan Change
1,486 ^INR	+0.45%		+0.21%	+19.19%

May. 27	Indian drugmakers to see FY25 revenue boost in key US market, says India Ratings and Research	RE
May. 23	Nomura Adjusts Cipla’s Price Target to INR1,535 From INR1,486, Keeps at Neutral	MT

Cipla Limited Announces Resignation of Jasdeep Singh as Chief Strategy Officer and Senior Management Personnel

May 14, 2024 at 11:31 am EDT

Cipla Limited notified that Mr. Jasdeep Singh, Chief Strategy Officer and Senior Management Personnel of the Company has resigned to pursue personal interests outside Cipla. His last working day is 31st May 2024.

Latest news about Cipla Limited

Indian drugmakers to see FY25 revenue boost in key US market, says India Ratings and Research	May. 27	RE
Nomura Adjusts Cipla’s Price Target to INR1,535 From INR1,486, Keeps at Neutral	May. 23	MT
Consumer Goods, Realty Push Indian Equities Higher on Wednesday	May. 22	MT
Cipla Arm Gets US FDA Final Nod for Lanreotide Injection	May. 22	MT
Cipla Limited Approves the Appointment of Dr. Balram Bhargava as an Independent Director	May. 17	CI
Indian Equities Extend Gains on Friday, Led by Real Estate, Auto and Metal Names	May. 17	MT
Cipla Invests INR260 Million More in Associate Achira Labs	May. 15	MT
Indian Equities Posts Mild Losses on Wednesday Ahead of US Consumer Inflation Data	May. 15	MT
INDIA STOCKS-Cipla lifts Indian shares at the open; Canara Bank rises on MSCI inclusion	May. 15	RE
Achira Labs Pvt. Ltd. announced that it expects to receive INR 260 million in funding from Cipla Limited	May. 14	CI
Cipla Limited Announces Resignation of Jasdeep Singh as Chief Strategy Officer and Senior Management Personnel	May. 14	CI
Promoter group to sell stake worth $316 million in India's Cipla, CNBC-TV18 reports	May. 14	RE
Indian Equities Close Higher on Tuesday, Led by Auto, Metal Stocks	May. 14	MT
Nomura Adjusts Cipla’s Price Target to INR1,486 From INR1,569, Keeps at Neutral	May. 14	MT
Indian Equities End Higher on Monday Despite Poll Worries, Foreign Selling	May. 13	MT
Jefferies Adjusts Cipla’s Price Target to INR1,400 From INR1,250, Keeps at Hold	May. 13	MT
Cipla's Consolidated Net Profit Climbs in Fiscal Q4; Shares Up 6%	May. 13	MT
INDIA STOCKS-Election worries, foreign selling spook Indian equities; volatility climbs	May. 13	RE
INDIA STOCKS-Indian shares fall as Tata Motors slides; inflation data awaited	May. 13	RE
Transcript : Cipla Limited, Q4 2024 Earnings Call, May 10, 2024	May. 10
Market Heavyweights Lifts Indian Equities to End Week Higher	May. 10	MT
India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says	May. 10	RE
India's Cipla beats Q4 profit estimates	May. 10	RE
Cipla Limited Recommends Payment of Final Dividend for the Financial Year Ended March 31, 2024	May. 10	CI
Cipla Limited Announces Retirement of S. Radhakrishnan as Non-Executive Director	May. 10	CI

Chart Cipla Limited

Duration

Period

More charts

Company Profile

Cipla specializes in development, manufacturing and marketing of pharmaceutical products. The group provides prescription products and OTC medicines for the treatment of cardiovascular, ophthalmic and dermatological diseases, respiratory troubles, cancers, allergies, infections etc. Besides, Cipla develops and sells veterinary products. Net sales by source of income break down between sale of products (96.9%) and services (3.1%). Net sales are distributed geographically as follows: India (39.4%), the United States (18.5%), South Africa (17%) and other (25.1%).

Sector

Pharmaceuticals

Calendar

2024-08-01 - Ex-dividend day for final dividend

Related indices

NIFTY 50 , NIFTY 100

More about the company

Income Statement Evolution

More financial data

Ratings for Cipla Limited

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,479 INR

Average target price

1,476 INR

Spread / Average Target

-0.21%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
CIPLA LIMITED	+19.19%	14.36B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+18.31%	42.25B
OTSUKA HOLDINGS CO., LTD.	+15.37%	21.27B
SANDOZ GROUP AG	+18.29%	15.23B
ZYDUS LIFESCIENCES LIMITED	+52.22%	12.74B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-12.40%	6.61B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.28%	5.66B
GEDEON RICHTER	+7.31%	4.8B

Generic Pharmaceuticals

Cipla Limited

Equities

CIPLA

INE059A01026

Pharmaceuticals

Cipla Limited Announces Resignation of Jasdeep Singh as Chief Strategy Officer and Senior Management Personnel

EPS Revisions